share_log

3: Initial statement of beneficial ownership of securities-Director Fry Simon Jeremy

3: Initial statement of beneficial ownership of securities-Director Fry Simon Jeremy

3:首次持股声明-董事 Fry Simon Jeremy
美股SEC公告 ·  2024/12/21 06:10

Moomoo AI 已提取核心信息

Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.
Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.
西蒙·杰里米·弗赖被任命为Conduit Pharmaceuticals Inc的董事,任职自2024年12月18日。该信息在向美国证券交易委员会提交的Form 3文件中披露,表明了证券的初步权益声明。文件显示,弗赖直接持有Conduit Pharmaceuticals普通股200,000股。这一 substantial 参股金融 表明了对公司的重大承诺,并将新董事的利益与其他股东的利益对齐。Form 3于2024年12月20日由弗赖签署,距要求声明的事件发生已过去两天。文件中未报告衍生证券,表明弗赖的所有权目前仅限于普通股。
西蒙·杰里米·弗赖被任命为Conduit Pharmaceuticals Inc的董事,任职自2024年12月18日。该信息在向美国证券交易委员会提交的Form 3文件中披露,表明了证券的初步权益声明。文件显示,弗赖直接持有Conduit Pharmaceuticals普通股200,000股。这一 substantial 参股金融 表明了对公司的重大承诺,并将新董事的利益与其他股东的利益对齐。Form 3于2024年12月20日由弗赖签署,距要求声明的事件发生已过去两天。文件中未报告衍生证券,表明弗赖的所有权目前仅限于普通股。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息